PCR Markets, 2024: qPCR, dPCR, Singleplex & Multiplex Markets - Down the Curve We Go
Dublin, Oct. 07, 2020 (GLOBE NEWSWIRE) -- The "PCR Markets: Forecasts for qPCR, dPCR, Singleplex & Multiplex Markets with Executive and Consultant Guides, Including Customized Forecasting and Analysis 2020 to 2024" report has been added to ResearchAndMarkets.com's offering.
The report forecasts the market size out to 2024 with the only analysis available that breaks out Singleplex and Multiplex testing markets. PCR has proved itself in the market. And the new generation of PCR, digital PCR promises to keep that success going. New levels of sensitivity have implications for Liquid Biopsy and Cancer Screening markets.
Lowering costs, improving outcomes and even helping in the battle against Anti Microbial Resistance. Learn about this market including the issues and outlooks. The two key trends of Point of Care Testing and Molecular Diagnostics are merging with spectacular success.
Key Questions
Are singleplex tests going to be obsolete?
Will routine cancer screening become a reality?
Will diagnostics move into the Physician's Office or even the Home?
Will digital PCR become the new lab standard?
Key Topics Covered:
1. Introduction and Market Definition
1.1 What are PCR Technologies?
1.2 PCR-New Horizons
1.2.1 PCR and Syndromic Testing
1.3 Market Definition
1.3.1 Market Size
1.3.2 Currency
1.3.3 Years
1.4 Methodology
1.4.1 Authors
1.4.2 Sources
1.5 U.S. Medical Market and laboratory Testing-Perspective
1.5.1 U.S. Medicare Expenditures for Laboratory Testing
2. PCR-Guide to PCR Technologies
2.0 PCR
2.1 Concepts
2.1.1 Method
2.2 Applications
2.2.1 Finding Specific DNA
2.2.2 Measuring DNA
2.2.3 Medical and diagnostic applications
2.2.3.1 Carrier, prenatal and tissue typing
2.2.3.2 Cancer Diagnosis and Management
2.2.3.3 Infectious disease-New Levels of Accuracy and Sensitivity
2.2.3.4 Forensic applications
2.2.3.5 Science and Research
2.3 PCR-Advantages and Disadvantages
2.4 Different Types of PCR
2.4.1 Simple Changes
2.4.1.1 Multiplex-PCR
2.4.1.2 VNTR PCR
2.4.1.3 Asymmetric PCR
2.4.1.4 Long PCR
2.4.1.5 Nested PCR
2.4.1.6 Quantitative PCR
2.4.1.7 Hot-start PCR
2.4.1.8 Touchdown PCR
2.4.1.9 Assembly PCR
2.4.1.10 Colony PCR
2.4.1.11 Suicide PCR
2.4.1.12 Cold PCR
2.4.2 Digital PCR
2.4.2.1 Droplet Digital PCR
2.4.2.2 Comparison between dPCR and Real-Time PCR (qPCR)
2.4.2.3 Digital PCR in Use
2.4.2.4 Digital PCR Commercial History
2.4.3 Isothermal PCR
3. Industry Overview
3.1 Players in a Dynamic Market
3.1.1 Academic Research Lab
3.1.2 Diagnostic Test Developer
3.1.3 Genomic Instrumentation Supplier
3.1.3.1 Cell Separation and Viewing Instrumentation Supplier
3.1.4 Pharmaceutical/Reagent Supplier
3.1.5 Independent Testing Lab
3.1.6 Public National/regional lab
3.1.7 Hospital lab
3.1.8 Physician Lab
3.1.9 Audit Body
3.1.10 Certification Body
4. Market Trends
4.1 Factors Driving Growth
4.1.1 A New Standard
4.1.2 Down the Curve We Go
4.1.3 Multiplexing
4.1.4 Syndromic Diagnostics Looks Unstoppable
4.1.5 The Genetic Blizzard
4.2 Factors Limiting Growth
4.2.1 The Cost Curve
4.2.2 The Other Guys
4.2.3 Systemic Roadblocks
4.3 Diagnostic Technology Development
4.3.1 The Instrumentation Curve
4.3.2 Shifting Role of Diagnostics
4.3.3 Diagnostics Moves Out of the Lab
4.3.3.1 What About Imaging?
4.3.4 Disruption Looms
4.3.5 The Next Five Years
5. PCR Recent Developments
5.1 Recent Developments-Importance and How to Use This Section
5.1.1 Importance of These Developments
5.1.2 How to Use This Section
QIAGEN Plans for Next-Generation Digital PCR Systems
Bioneer HIV-1 Dx Kit Gets Korea FDA Approval
New PCR Technology: Transfer-PCR (tPCR) Applications
NimaGen Licenses PCR Tech from Salisbury NHS Foundation Trust
Natera Applies Massively Multiplexed PCR to Kidney Transplants
Paragon Genomics, MGI Tech Form Distribution Alliance
Synlab Pharma, Biotype Collaborate on Gastrointestinal, Endometrial Cancers
Qiagen, NeuMoDx Ink Partnership, Merger Agreement
Bruker to Acquire Majority in Hain Lifescience GmbH
Curetis to Cut 30 Percent of Workforce as Part of Strategic Restructuring
Cancer Early Detection Firm Ark Launches With $40M Series A Investment
PredictImmune Wins 100K Grant for Study of IBD Prognostic
Biocartis, AstraZeneca Partner on European Lung Cancer Biomarker Study
llumina Ventures Leads 16M Series A Investment in Digital PCR Firm Stilla Technologies
Bio-Rad Wins USDA Food Safety Testing Contract
Luminex, XCR Diagnostics Sign Nucleic Acid Amplification Tech Licensing Deal
6. Profiles of Key PCR Companies
Abbott Diagnostics (Alere)
Accelerate Diagnostics
Agilent
Alveo Technologies
Applied BioCode
Atlas Genetics
Aus Diagnostics
BD Diagnostics
Biocartis
BioFire Diagnostics
bioMrieux
Bioneer
Bio-Rad Laboratories
Bosch Healthcare Solutions GmbH
Bruker
Cepheid
Curetis
Diagenode Diagnostics
Diasorin
Fluidigm
Fusion Genomics.
GenePOC Diagnostics
GenMark Dx
Hologic
Invetech
Janssen Diagnostics
Karius
Lexigene
Luminex
Mesa Biotech
Mobidiag
Nanomix
Panagene
Precipio
Primerdesign
Prominex
Qiagen (Statdx)
Quantumdx
Roche Molecular Diagnostics
Seegene
Stilla Technologies
Siemens Healthineers (Fast Track Diagnostics)
SkylineDx
T2 Biosystems
Thermo Fisher
Veramarx
XCR Diagnostics
7. The PCR Markets
7.1 PCR-Global Market Overview by Country
7.1.1 Table-Global Market by Country
7.1.2 Chart-Global Market by Country
8. Global PCR Markets-By Application
8.1 Global Market by Application-Overview
8.2 PCR Clinical Multiplex
8.3 PCR Clinical Singleplex
8.4 PCR Research
8.5 PCR Forensic
8.6 PCR Other
9. Global PCR Markets-By Technology
9.1 Global Market by Technology-Overview
9.2 qPCR
9.3 dPCR
9.4 Other PCR
Appendices
I. United States Medicare System: 2018 Clinical Laboratory Fees Schedule-National Limit and Midpoint
II. FDA Approved Microbial Tests
For more information about this report visit https://www.researchandmarkets.com/r/et0sd5
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900